These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 26904465)

  • 21. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
    Lupsa BC; Inzucchi SE
    Diabetologia; 2018 Oct; 61(10):2118-2125. PubMed ID: 30132031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
    Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
    Brunton SA
    Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
    Katz PM; Leiter LA
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacovigilance of Sodium-Glucose Cotransporter-2 Inhibitors for Genital Fungal Infections and Urinary Tract Infections: A Review of the Food and Drug Administration Adverse Event Reporting System Database.
    Mohammad H; Borja-Hart N
    J Pharm Technol; 2018 Aug; 34(4):144-148. PubMed ID: 34860970
    [No Abstract]   [Full Text] [Related]  

  • 27. Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology.
    Tanaka A; Node K
    J Cardiol; 2017 Mar; 69(3):501-507. PubMed ID: 28043708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
    Jabbour SA
    Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary.
    Mascolo A; Di Napoli R; Balzano N; Cappetta D; Urbanek K; De Angelis A; Scisciola L; Di Meo I; Sullo MG; Rafaniello C; Sportiello L
    Front Cardiovasc Med; 2022; 9():1010693. PubMed ID: 36211584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction.
    Brust-Sisti L; Rudawsky N; Gonzalez J; Brunetti L
    Pharmacy (Basel); 2022 Nov; 10(6):. PubMed ID: 36548322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.
    Prasanna Kumar KM; Ghosh S; Canovatchel W; Garodia N; Rajashekar S
    Indian J Endocrinol Metab; 2017; 21(1):196-209. PubMed ID: 28217522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.
    Cavaiola TS; Pettus J
    Diabetes Metab Syndr Obes; 2018; 11():133-148. PubMed ID: 29695924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SGLT2 inhibitors.
    Dardi I; Kouvatsos T; Jabbour SA
    Biochem Pharmacol; 2016 Feb; 101():27-39. PubMed ID: 26362302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    J Pharmacol Sci; 2016 Jul; 131(3):198-208. PubMed ID: 27430987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardio-renal protection with empagliflozin.
    MacIsaac RJ; Jerums G; Ekinci EI
    Ann Transl Med; 2016 Oct; 4(20):409. PubMed ID: 27867961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin.
    Ahmann A
    Drugs Context; 2015; 4():212288. PubMed ID: 26633984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes.
    Papakitsou I; Vougiouklakis G; Elisaf MS; Filippatos TD
    Clin Pharmacol; 2019; 11():133-143. PubMed ID: 31572020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes.
    Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B
    Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.